- Home
- MCRB vs TNXP Comparison
MCRB vs TNXP Comparison
Compare MCRB & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- TNXP
- Stock Information
- Founded
- MCRB 2010
- TNXP 2007
- Country
- MCRB United States
- TNXP United States
- Employees
- MCRB N/A
- TNXP N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- TNXP Health Care
- Exchange
- MCRB Nasdaq
- TNXP Nasdaq
- Market Cap
- MCRB 141.9M
- TNXP 116.9M
- IPO Year
- MCRB 2015
- TNXP N/A
- Fundamental
- Price
- MCRB $0.37
- TNXP $15.71
- Analyst Decision
- MCRB Hold
- TNXP Strong Buy
- Analyst Count
- MCRB 5
- TNXP 2
- Target Price
- MCRB $4.00
- TNXP $585.00
- AVG Volume (30 Days)
- MCRB 1.3M
- TNXP 1.5M
- Earning Date
- MCRB 05-07-2025
- TNXP 05-12-2025
- Dividend Yield
- MCRB N/A
- TNXP N/A
- EPS Growth
- MCRB N/A
- TNXP N/A
- EPS
- MCRB 0.00
- TNXP N/A
- Revenue
- MCRB N/A
- TNXP $10,094,000.00
- Revenue This Year
- MCRB N/A
- TNXP $12.17
- Revenue Next Year
- MCRB N/A
- TNXP $789.15
- P/E Ratio
- MCRB $474.36
- TNXP N/A
- Revenue Growth
- MCRB N/A
- TNXP 29.94
- 52 Week Low
- MCRB $0.46
- TNXP $6.76
- 52 Week High
- MCRB $1.53
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- MCRB 28.34
- TNXP 44.80
- Support Level
- MCRB $0.36
- TNXP $15.23
- Resistance Level
- MCRB $0.67
- TNXP $22.25
- Average True Range (ATR)
- MCRB 0.07
- TNXP 2.36
- MACD
- MCRB -0.02
- TNXP -0.54
- Stochastic Oscillator
- MCRB 2.71
- TNXP 16.54
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.